NNNN logo

ANBIO BIOTECHNOLOGY LTD

NNNNNASDAQ
πŸ† #2808 by market capUS Equity
$3.72β–² $0.00 (+0.00%)
Latest quote
πŸ””
Track NNNN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.0%
7dβ–Ό 0.8%
14dβ–² 11.9%
30dβ–Ό 40.1%
ytdβ–Ό 87.4%
1yβ–Ό 82.6%
🏦Market Cap
$163M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-5.7%
Declining
πŸ“ŠGross Margin
89.0%
High
πŸ’΅FCF Margin
15.7%
Healthy
βš–οΈP/S Ratio
40.3x
Expensive
Otter Score
56
Fair

Trading Snapshot

Day Range
$3.72 – $3.75
52-Week Range
$3.09 – $44.73
Volume (shares)
829
Avg Volume (shares)
β€”
Shares Outstanding
43.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$5M
P/E Ratio
52.3
P/S Ratio
40.3x
EPS (TTM)
$0.23
Dividend Yield
β€”
Dilution (1yr)
+3.8%
NNNN logo

ANBIO BIOTECHNOLOGY LTD

NNNN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9Mβ–² +5.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
87.2%β–² +21.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$6Mβ–² +189.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$7Mβ–Ό βˆ’423.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
43.9Mβ–² +3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mβ–Ό βˆ’$4M YoY
StockOtter Β· stockotter.space

About ANBIO BIOTECHNOLOGY LTD

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100
Analyst data unavailable.

Latest News & Updates

News unavailable.